Results 151 to 160 of about 24,697,135 (341)
TRPM8 levels determine tumor vulnerability to channel agonists
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo+18 more
wiley +1 more source
Detection of Immune Response Against Synthetic Polymers of Amino Acids Employing the Plaque-Forming Cell System [PDF]
Patricia Walsh+2 more
openalex +1 more source
COVID-19 and the human innate immune system
J. Schultze, A. Aschenbrenner
semanticscholar +1 more source
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte+10 more
wiley +1 more source
Problems Encountered in Double Diffusion Analysis in Agar of Hapten Specific Immune Systems [PDF]
William E. Paul, Baruj Benacerraf
openalex +1 more source
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song+11 more
wiley +1 more source
Heat labile and heat stable factors and antibodies in normal and immune sera against T-system bacteriophages [PDF]
Enver Tall Çetin
openalex +1 more source
Background Age‐related primary sarcopenia and end‐stage renal disease (ESRD)–related muscle wasting are discrete entities; however, both manifest as a decline in skeletal muscle mass and strength.
Daiki Setoyama+14 more
doaj +1 more source
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source
Studies on the Role of Complement in the Immune Clearance of Escherichia Coli and Rat Erythrocytes by the Reticuloendothelial System in Mice [PDF]
Hans L. Spiegelberg+2 more
openalex +1 more source